Coherus Oncology (NASDAQ:CHRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Coherus Oncology (NASDAQ:CHRS) posted its earnings results on Monday. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01, FiscalAI reports. Coherus Oncology had a net margin of 397.30% and a negative return on equity of 192.84%. The firm had revenue of $12.31 million during the quarter, compared to analysts’ expectations of $14.22 million.

Here are the key takeaways from Coherus Oncology’s conference call:

• LOQTORZI net sales rose 61% year-over-year to $11.8M in Q1, new patient starts hit an all-time high, and management expects 10%–15% average quarterly demand growth in 2026 despite a weather-driven seasonal Q1 dip.
• The randomized CATALYST-202 HCC study (72 patients) has completed target accrual, with initial data and planned biomarker reads (IL-27 and circulating tumor DNA) expected around mid-year to assess contribution and earlier signals of efficacy.
• The tagmokitug CCR8 program is actively enrolling multiple cohorts (head & neck, upper GI, ESCC, MSS CRC) and launching a J&J pasritamig prostate cohort under a multi-cohort protocol, but the CCR8 field shows mixed results so clinical outcomes remain uncertain.
• Management emphasizes that tagmokitug meets their “right drug” pharmacology criteria (linear PK, potency, dose-dependent target effects and acceptable safety), which they cite as a differentiator versus some paused CCR8 programs.
• Coherus strengthened liquidity with a $54M net follow-on equity raise and ended Q1 with $167M in cash and investments, which management says is sufficient to fund key 2026–2027 data readouts and near-term development priorities.

Coherus Oncology Stock Up 2.6%

NASDAQ CHRS traded up $0.05 during trading hours on Wednesday, reaching $1.76. 1,835,485 shares of the company’s stock traded hands, compared to its average volume of 1,897,154. Coherus Oncology has a 52-week low of $0.71 and a 52-week high of $2.62. The firm has a market cap of $270.65 million, a PE ratio of 1.05 and a beta of 1.01. The firm has a 50-day simple moving average of $1.74 and a 200 day simple moving average of $1.63. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.47 and a quick ratio of 1.45.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. grew its position in Coherus Oncology by 2.5% during the third quarter. Jefferies Financial Group Inc. now owns 325,625 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 8,000 shares during the period. Corient Private Wealth LLC grew its position in Coherus Oncology by 20.0% during the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 10,000 shares during the period. BNP Paribas Financial Markets grew its position in Coherus Oncology by 108.2% during the third quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 13,832 shares during the period. Quarry LP bought a new stake in Coherus Oncology during the third quarter valued at approximately $26,000. Finally, Ieq Capital LLC grew its position in Coherus Oncology by 24.9% during the fourth quarter. Ieq Capital LLC now owns 79,128 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 15,751 shares during the period. 72.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on CHRS. Guggenheim began coverage on shares of Coherus Oncology in a research report on Monday. They issued a “buy” rating and a $12.00 target price for the company. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Oppenheimer began coverage on shares of Coherus Oncology in a research report on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 target price for the company. Finally, Weiss Ratings raised shares of Coherus Oncology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.67.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.